CoLucid Jumps 80% After Migraine Drug Achieves Primary And Key Secondary Endpoints
Investors of CoLucid Pharmaceuticals Inc (NASDAQ: CLCD) greeted positive news from the company that its SAMURAI final stage study evaluating lasmiditan achieved both the primary and key secondary efficacy endpoints. The company claimed that lasmiditan was well tolerated.
The company said SAMURAI was a randomized, double-blind, placebo-controlled parallel group trial meant to assess the efficacy and safety of lasmiditan (100 mg and 200 mg) in comparison to placebo. The company indicated that SAMURAI is the first of two final stage pivotal trials of lasmiditan and that each being conducted under a Special Protocol Assessment agreement with the FDA.
CoLucid pointed out that the primary endpoint of SAMURAI was the efficacy of lasmiditan, both 100 mg and 200 mg, versus placebo based on freedom from migraine headache pain two hours following the dosage. Similarly, the key secondary endpoint was the efficacy of lasmiditan based on freedom from the most bothersome associated symptom (MBS) of migraine (nausea, phonophobia or photophobia) two hours following the dosage.
President and CEO Thomas Mathers said, "The study demographics represented the largest group of patients diagnosed and treated for migraine in the United States: primarily woman over the age of 40. Most patients, regardless of gender, had either CVRF or cardiovascular conditions. Currently, the use of prescription drug treatments in general, and triptans specifically, is less in these patients as compared to migraine patients with no CVRF."
Following the news, the stock jumped $9.04, or 84.8 percent, to $19.43.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.